Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$19.47 ▼ -0.22
(-1.12%)
MKT CAP: $4.27B • VOL: 1.95M
52W L $6 52W H $21
ROARABLE / RQD
D- • 35/100
PIOTROSKI
4 / 9
RLAY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $15.4M | $10.0M | $25.5M |
| YoY Revenue Growth % | +53.4% | -60.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$302.7M | -$372.5M | -$373.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$276.5M | -$337.7M | -$342.0M |
| EBITDA (Normalized) | -$302.4M | -$370.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$235.5M | -$249.1M | -$300.3M |
| Capital Expenditures (CapEx) | $410.0K | $2.0M | — |
| Free Cash Flow (FCF) | -$235.9M | -$251.1M | -$300.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $84.0M | $124.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $567.1M | $777.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RLAY.